Google
GLTO — GALECTO INC (Healthcare >> Biotechnology)
GLTO FAQ
What is GLTO's ROE?
GALECTO INC reports a Return on Equity (ROE) of -46.07%.
What is GLTO's dividend yield?
GALECTO INC offers a dividend yield of 0.00%.
What is GLTO's Deepscope Quality Score?
Deepscope rates GLTO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GLTO?
Deepscope's AI Timing Score for GLTO is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GLTO belong to?
GALECTO INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 24.45
Price
0.32
(1.33%)
Day Change
|
|
|---|
GLTO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 24.45 |
| PBV / Sector |
3.39 / 4.63
|
| Earning Per Share | -3.33 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
6.16 M
|
| Average 1W Daily Value |
4.74 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | GLTO |
| Name | GALECTO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.24 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,728.29 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Ole Maaloes Vej 3, Copenhagen, Denmark, 2200
Phone: 45 70 70 52 10
Website: https://galecto.com
Sector: Healthcare >> Biotechnology
Description: Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
